# A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

Study · id `cardio:ct-nct03882970` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03882970](<https://clinicaltrials.gov/study/NCT03882970>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03882970

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1444 participants.

## Technical summary

Registry record NCT03882970. Randomized; no masking; primary purpose treatment. Start 2019-04-01 (actual); primary completion 2020-12-11 (actual). Results posted on 2022-01-19.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1444 participants (enrolled count; ClinicalTrials.gov record NCT03882970, source copy `cardio:ctgov-nct03882970-2022-01-19`, retrieved 2026-10-26)
- Started: 2019-04-01 (actual) (ClinicalTrials.gov record NCT03882970, source copy `cardio:ctgov-nct03882970-2022-01-19`, retrieved 2026-10-26)
- Primary completion: 2020-12-11 (actual) (ClinicalTrials.gov record NCT03882970, source copy `cardio:ctgov-nct03882970-2022-01-19`, retrieved 2026-10-26)
- Completion: 2021-01-04 (actual) (ClinicalTrials.gov record NCT03882970, source copy `cardio:ctgov-nct03882970-2022-01-19`, retrieved 2026-10-26)
- Results first posted: 2022-01-19 (ClinicalTrials.gov record NCT03882970, source copy `cardio:ctgov-nct03882970-2022-01-19`, retrieved 2026-10-26)
- Countries: United States; Argentina; Austria; Greece; Hungary; Italy; Poland; Puerto Rico; Romania; South Korea; Spain; Taiwan; Ukraine (ClinicalTrials.gov record NCT03882970, source copy `cardio:ctgov-nct03882970-2022-01-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03882970-2022-01-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
- Acronym: SURPASS-3
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Tirzepatide
- Intervention (Drug): Insulin Degludec
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial (`cardio:pubmed-34370970`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial (`cardio:pubmed-35468321`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial (`cardio:pubmed-35468325`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial (`cardio:pubmed-40318682`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI (`cardio:pubmed-42576670`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 125d6ce9874182c84f4bcb1214bd6a30346d4d1e54f4ae64c57132abbb1b0465
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
